GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1

Life Sciences

Volumn 82, Issue 9-10, 2008, Pages 460-466

  Yamamoto, Daisuke ^a   Ikeshita, Nobuko ^a   Matsubara, Takako ^a   Tasaki, Hiromitsu ^a   Herningtyas, Elizabeth Henny ^b   Toda, Keizo ^a   Iida, Keiji ^b   Takahashi, Yutaka ^b   Kaji, Hidesuke ^c   Chihara, Kazuo ^b   Okimura, Yasuhiko ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Neurology and Hematology/Oncology   (Japan)

^c UNIVERSITY OF HYOGO   (Japan)

Author keywords

Atrogin 1; GHRP 2; IGF I; MuRF1; Muscle specific ubiquitin ligases

Indexed keywords

DEXAMETHASONE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; MUSCLE RING FINGER 1 PROTEIN; PRALMORELIN; PROTEIN ATROGIN 1; SOMATOMEDIN C; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HORMONE RELEASE; MALE; MUSCLE ATROPHY; MUSCLE CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION; RNA EXTRACTION; SEQUENCE ANALYSIS; SOLEUS MUSCLE;

ANIMALS; CELL LINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GLUCOCORTICOIDS; MALE; MICE; MUSCLE CELLS; MUSCLE PROTEINS; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GHRELIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN-PROTEIN LIGASES;

RATTUS;

EID: 39149139958     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.11.019     Document Type: Article

References (37)

1. Alzghoul M.B., Gerrard D., Watkins B.A., and Hannon K. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. The FASEB Journal 18 1 (2004) 221-223
2. Baracos V.E., Devivo C., Hoyle D.H., and Goldberg A.L. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. The American Journal of Physiology-Endocrinology and Metabolism 268 5 Pt 1 (1995) E996-E1006
3. Bodine S.C., Latres E., Baumhueter S., Lai V.K., Nunez L., Clarke B.A., Poueymirou W.T., Panaro F.J., Na E., Dharmarajan K., Pan Z.Q., Valenzuela D.M., Dechiara T.M., Stitt T.N., Yancopoulos G.D., and Glass D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 5547 (2001) 1704-1708
4. Bowers C.Y., Granda R., Mohan S., Kuipers J., Baylink D., and Veldhuis J.D. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. The Journal of Clinical Endocrinology and Metabolism 89 5 (2004) 2290-2300
5. Cheng K., Chan W.W., Barreto Jr. A., Convey E.M., and Smith R.G. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′5′ -monophosphate accumulation in rat primary pituitary cell culture. Endocrinology 124 (1989) 2791-2798
6. Day C.S., Buranapanitkit B., Riano F.A., Tomaino M.M., Somogyi G., Sotereanos D.G., Kuroda R., and Huard J. Insulin growth factor-1 decreases muscle atrophy following denervation. Microsurgery 22 4 (2002) 144-151
7. Falduto M.T., Young A.P., and Hickson R.C. Exercise inhibits glucocorticoid-induced glutamine synthetase expression in red skeletal muscles. American Journal of Physiology-Cell Physiology 262 1 Pt 1 (1992) C214-C220
8. Falduto M.T., Young A.P., and Hickson R.C. Exercise interrupts ongoing glucocorticoid-induced muscle atrophy and glutamine synthetase induction. American Journal of Physiology-Cell Physiology 263 6 Pt 1 (1992) E1157-E1163
9. Frost R.A., Nystrom G.J., and Lang C.H. Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 144 5 (2003) 1770-1779
10. Gilson H., Schakman O., Combaret L., Lause P., Grobet L., Attaix D., Ketelslegers J.M., and Thissen J.P. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148 1 (2007) 452-460
11. Giustina A., and Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews 19 6 (1998) 717-797
12. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., and Goldberg A.L. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 98 25 (2001) 14440-14445
13. Granado M., Priego T., Martin A.I., Villanua M.A., and Lopez-Calderon A. Ghrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. American Journal of Physiology-Endocrinology and Metabolism 289 6 (2005) E1007-E1014
14. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K.K., Mckee K.K., Pong S.S., Chaung L.Y., Elbrecht A., Dashkevicz M., Heavens R., Rigby M., Sirinathsinghji D.J., Dean D.C., Melillo D.G., Patchett A.A., Nargund R., Griffin P.R., Demartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., and Van Der Ploeg L.H. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 5277 (1996) 974-977
15. Kanda F., Takatani K., Okuda S., Matsushita T., and Chihara K. Preventive effects of insulinlike growth factor-I on steroid-induced muscle atrophy. Muscle & Nerve 22 2 (1999) 213-217
16. Kandarian S.C., and Jackman R.W. Intracellular signaling during skeletal muscle atrophy. Muscle & Nerve 33 2 (2006) 155-165
17. Kayali A.G., Young V.R., and Goodman M.N. Sensitivity of myofibrillar proteins to glucocorticoid-induced muscle proteolysis. American Journal of Physiology-Endocrinology and Metabolism 252 5 Pt 1 (1987) E621-E626
18. King A.P., and Carter-Su C. Dexamethasone-induced antagonism of growth hormone (GH) action by down-regulation of GH binding in 3T3-F442A fibroblasts. Endocrinology 136 11 (1995) 4796-4803
19. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 6762 (1999) 656-660
20. Lecker S.H., Jagoe R.T., Gilbert A., Gomes M., Baracos V., Bailey J., Price S.R., Mitch W.E., and Goldberg A.L. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. The FASEB journal 18 1 (2004) 39-51
21. Ma K., Mallidis C., Bhasin S., Mahabadi V., Artaza J., Gonzalez-Cadavid N., Arias J., and Salehian B. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. American Journal of Physiology-Endocrinology and Metabolism 285 2 (2003) E363-E371
22. Mckee K.K., Palyha O.C., Feighner S.D., Hreniuk D.L., Tan C.P., Phillips M.S., Smith R.G., Van Der Ploeg L.H., and Howard A.D. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Molecular Endocrinology 11 4 (1997) 415-423
23. Murata M., Okimura Y., Iida K., Matsumoto M., Sowa H., Kaji H., Kojima M., Kangawa K., and Chihara K. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. The Journal of Biological Chemistry 277 7 (2002) 5667-5674
24. Nijland E.A., Strasburger C.J., Popp-Snijders C., Van Der Wal P.S., and Van Der Veen E.A. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. European Journal of Endocrinology 139 4 (1998) 395-401
25. Papotti M., Ghe C., Cassoni P., Catapano F., Deghenghi R., Ghigo E., and Muccioli G. Growth hormone secretagogue binding sites in peripheral human tissues. The Journal of Clinical Endocrinology and Metabolism 85 10 (2000) 3803-3807
26. Pierno S., De Luca A., Desaphy J.F., Fraysse B., Liantonio A., Didonna M.P., Lograno M., Cocchi D., Smith R.G., and Camerino D.C. Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor. British Journal of Pharmacology 139 3 (2003) 575-584
27. Pihoker C., Middleton R., Reynolds G.A., Bowers C.Y., and Badger T.M. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. The Journal of Clinical Endocrinology Metabolism 80 10 (1995) 2987-2992
28. Price S.R., Bailey J.L., and England B.K. Necessary but not sufficient: the role of glucocorticoids in the acidosis-induced increase in levels of mRNAs encoding proteins of the ATP-dependent proteolytic pathway in rat muscle. Mineral Electrolyte Metabolism 22 1-3 (1996) 72-75
29. Sacheck J.M., Ohtsuka A., Mclary S.C., and Goldberg A.L. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. American Journal of Physiology-Endocrinology and Metabolism 287 4 (2004) E591-E601
30. Sawada H., Sugihara H., Onose H., Minami S., Shibasaki T., and Wakabayashi I. Effect of D-Ala-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2 (KP-102) on GH secretion in urethan-anesthetized rats. Regulatory Peptides 53 3 (1994) 195-201
31. Schakman O., Gilson H., De Coninck V., Lause P., Verniers J., Havaux X., Ketelslegers J.M., and Thissen J.P. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146 4 (2005) 1789-1797
32. Smith R.G., Cheng K., Schoen W.R., Pong S.S., Hickey G., Jacks T., Butler B., Chan W.W., Chaung L.Y., and Judith F. A nonpeptidyl growth hormone secretagogue. Science 260 5114 (1993) 1640-1643
33. Stitt T.N., Drujan D., Clarke B.A., Panaro F., Timofeyva Y., Kline W.O., Gonzalez M., Yancopoulos G.D., and Glass D.J. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 14 3 (2004) 395-403
34. Tiao G., Hobler S., Wang J.J., Meyer T.A., Luchette F.A., Fischer J.E., and Hasselgren P.O. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. Journal of Clinical Investigation 99 2 (1997) 163-168
35. Tischler M.E., Rosenberg S., Satarug S., Henriksen E.J., Kirby C.R., Tome M., and Chase P. Different mechanisms of increased proteolysis in atrophy induced by denervation or unweighting of rat soleus muscle. Metabolism 39 7 (1990) 756-763
36. Tschop M., Statnick M.A., Suter T.M., and Heiman M.L. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 143 2 (2002) 558-568
37. Wu D., Chen C., Zhang J., Bowers C.Y., and Clarke I.J. The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3′ 5′ -monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs. Journal of Endocrinology 148 2 (1996) 197-205